DeepMed Research

SinoCelltech Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis

Phase 2

Not yet recruiting

Conditions: Axial Spondyloarthritis

Interventions: Drug: SCT650C

First Posted Date: 2024-01-09

Last Posted Date: 2024-01-09

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 168

Registration Number: NCT06197009

Locations: 🇹🇷
Hacettepe University Faculty of Medicine, Ankara, Hacettepe Mh., Turkey

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

Phase 3

Active, not recruiting

Conditions: HPV InfectioN
HPV-Related Carcinoma

Interventions: Biological: placebo
Biological: Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）

First Posted Date: 2023-09-18

Last Posted Date: 2023-09-18

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 18000

Registration Number: NCT06041061

Locations: 🇨🇳
Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China
🇨🇳
Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China
🇨🇳
Shanxi Center for Disease Control and Prevention, Taiyuan, Shanxi, China

and more 2 locations

A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines

Phase 2

Not yet recruiting

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Biological: SCTV01E-2
Biological: SCTV01E

First Posted Date: 2023-07-06

Last Posted Date: 2023-07-06

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 600

Registration Number: NCT05933512

Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

Phase 1

Not yet recruiting

Conditions: Autoimmune Disease

Interventions: Drug: SCT650C

First Posted Date: 2023-06-08

Last Posted Date: 2023-06-08

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 32

Registration Number: NCT05894707

Locations: 🇦🇺
Linear Clinical Research - Harry Perkins, Nedlands, Western Australia, Australia
🇦🇺
Linear Clinical Research - Joonadalup, Joondalup, Western Australia, Australia
🇦🇺
Linear Clinical Research - B Block, Nedlands, Western Australia, Australia

Study on the Antibody Level Against SARS-CoV-2 （COVID-19）in Dazhu County in 2023

Recruiting

Conditions: COVID-19

First Posted Date: 2023-03-07

Last Posted Date: 2023-03-08

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 20000

Registration Number: NCT05758675

Locations: 🇨🇳
Dazhu County Center for Disease Control and Prevention, Dazhou, Sichuan, China

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People

Phase 3

Not yet recruiting

Conditions: COVID-19 SARS-CoV-2 Infection

Interventions: Biological: SCTV01E
Biological: CoronaVac

First Posted Date: 2023-01-13

Last Posted Date: 2023-01-13

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 6000

Registration Number: NCT05683561

A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine

Phase 2

Completed

Conditions: COVID-19 Pandemic

Interventions: Biological: SCTV01E
Biological: Placebo (normal saline)

First Posted Date: 2022-12-15

Last Posted Date: 2024-02-08

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 518

Registration Number: NCT05652543

Locations: 🇨🇳
Dazhu County Center for Disease Control and Prevention, Dazhou, Si Chuan, China
🇨🇳
Lianshui County Center for Disease Control and Prevention, Lianshui, Jiangsu, China
🇨🇳
Jiangsu Center for Disease Control and Prevention, Nanjing, Jiangsu, China

and more 1 locations

SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Recruiting

Conditions: Head and Neck Squamous Carcinoma

Interventions: Drug: SCT-I10A
Drug: SCT200
Drug: paclitaxel
Drug: docetaxel

First Posted Date: 2022-09-23

Last Posted Date: 2022-09-23

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 120

Registration Number: NCT05552807

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, China

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years

Phase 2

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Biological: SCTV01E on D0
Biological: SCTV01E-1 on D0
Biological: SCTV01E on D28
Biological: SCTV01E on D120
Biological: SCTV01E-1 on D28
Biological: SCTV01E-1 on D120
Biological: SCTV01E on D150
Biological: SCTV01E-1 on D150

First Posted Date: 2022-08-31

Last Posted Date: 2022-08-31

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 400

Registration Number: NCT05522829

This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Phase 3

Recruiting

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: SCT510A
Drug: Ranibizumab

First Posted Date: 2022-07-29

Last Posted Date: 2023-02-16

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 446

Registration Number: NCT05480293

Locations: 🇨🇳
Beijing Tongren Hospital, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy